• DOI:10.1016/j.jacc.2012.11.022
Corpus ID: 205552091

Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

@article{Berman2013PhaseIS,
  title={Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.},
  author={D. Berman and J. Maddahi and B. Tamarappoo and J. Czernin and R. Taillefer and J. Udelson and C. Gibson and M. Devine and J. Lazewatsky and G. Bhat and Dana Washburn},
  journal={Journal of the American College of Cardiology},
  year={2013},
  volume={61 4},
  pages={
          469-477
        }
}

D. Berman, J. Maddahi, +8 authors Dana Washburn

Published 2013

Medicine

Journal of the American College of Cardiology

OBJECTIVES This was a phase II trial to assess flurpiridaz F 18 for safety and compare its diagnostic performance for positron emission tomography (PET) myocardial perfusion imaging (MPI) with Tc-99m single-photon emission computed tomography (SPECT) MPI with regard to image quality, interpretative certainty, defect magnitude, and detection of coronary artery disease (CAD) (≥50% stenosis) on invasive coronary angiography (ICA). BACKGROUND In pre-clinical and phase I studies, flurpiridaz F 18… CONTINUE READING

View on PubMed

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed